Topical tapinarof cream showed significant improvement of moderate to severe atopic dermatitis while being well tolerated by adults and children down to age 2 years, according to two phase 3 clinical trials.
“These are essentially the flagship results for the efficacy and pivotal studies of tapinarof in both adults and children,” Jonathan I. Silverberg, MD, PhD, MPH, associate professor of dermatology at George Washington University and the study’s main author, told Healio. “These will be the crucial data that will support the FDA approval and approval in other regions